Comprehensive Identification of Somatic Mutations in Chronic Lymphocytic Leukemia  by Bergsagel, P. Leif & Kuehl, W. Michael
Cancer Cell
PreviewsHu, Y., Swerdlow, S., Duffy, T.M., Weinmann, R.,
Lee, F.Y., and Li, S. (2006). Proc. Natl. Acad. Sci.
USA 103, 16870–16875.Kuroda, J., Puthalakath, H., Cragg, M.S., Kelly,
P.N., Bouillet, P., Huang, D.C., Kimura, S., Ott-
mann, O.G., Druker, B.J., Villunger, A., et al.(2006). Proc. Natl. Acad. Sci. USA 103, 14907–
14912.O’Hare, T., Shakespeare, W.C., Zhu, X., Eide, C.A.,
Rivera, V.M., Wang, F., Adrian, L.T., Zhou, T.,
Huang, W.S., Xu, Q., et al. (2009). Cancer Cell 16,
401–412.Cancer CWendel, H.G., de Stanchina, E., Cepero, E., Ray,
S., Emig, M., Fridman, J.S., Veach, D.R., Born-
mann, W.G., Clarkson, B., McCombie, W.R.,
et al. (2006). Proc. Natl. Acad. Sci. USA 103,
7444–7449.
Williams, R.T., Roussel, M.F., and Sherr, C.J.
(2006). Proc. Natl. Acad. Sci. USA 103, 6688–6693.Comprehensive Identification of Somatic Mutations
in Chronic Lymphocytic LeukemiaP. Leif Bergsagel1 and W. Michael Kuehl2,*
1Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ, USA
2Genetics Branch, National Cancer Institute, Bethesda, MD, USA
*Correspondence: wmk@helix.nih.gov
DOI 10.1016/j.ccr.2011.06.023
Massively parallel sequencing enables the sequencing of whole genomes, exomes, and transcriptomes from
many tumor samples. Thus, it now is possible to comprehensively identify somatic mutations, including
single base changes, deletions, insertions, and genomic rearrangements. Early results for hematopoietic
tumors show great promise, but many questions remain to be answered.Improved methods for sequencing the
human genome at an increasingly lower
cost are now being applied to all kinds
of tumors (Lander, 2011). A recent paper
in Nature (Puente et al., 2011) offers
a glimpse of the power of integrating
genomic technologies, including global
sequence analysis, in B cell chronic
lymphocytic leukemia (CLL). Genomic
analysis started from an in-depth analysis
of four patients representing the two
major molecular subtypes of CLL: two
with and two without somatic hypermuta-
tion of the immunoglobulin heavy chain
variable region (IGHV). Paired advanced
tumor and normal blood cells isolated
before and after treatment, respectively,
were studied using multiple independent
technologies: whole genome sequencing
(WGS); mate pair sequencing of 2.5 kb
DNA fragments for efficient detection of
DNA rearrangements; and chip analyses
for single nucleotide polymorphisms
(SNPs), DNA copy number, and RNA
expression. This allowed the authors to
determine that the sequencing identified
99.4% of the heterozygous SNPs. Impor-
tantly, for a subset of the putative somatic
mutations, they were able to validate 96%
by Sanger sequencing. They foundapproximately 1000 somatic substitutions
per CLL genome. The pattern of base
changes and dinucleotide context
differed for the IGHV-mutated and IGHV-
unmutated tumors. The authors sug-
gested that the higher frequency of A > T
and C > G transversions in the IGHV-
mutated cases was consistent with their
introduction by the error prone-poly-
merase h during somatic hypermutation
in immunoglobulin genes. Altogether,
they identified changes in the protein-
coding region of 45 genes in the four
tumors, including 41 nonsynonymous
single base substitutions and 5 inser-
tions/deletions (indels). Typically, CLL
have only a limited number of genomic re-
arrangements. The comprehensive mate
pair analyses enabled the authors to iden-
tify and characterize ten large genomic
alterations, six of which—including large
13q14 deletions in three tumors—have
been reported previously in CLL.
Focusing on the 26mutated, expressed
genes, Puente et al. (2011) then extended
these findings to a cohort of 169 CLL pa-
tients. Using a clever pooled-sequencing
strategy, they determined that other CLL
tumors had mutations, suggesting identi-
fication of four driver genes: NOTCH1,12.2%; MYD88, 2.9%; XPO, 2.4%; and
KLHL6, 1.8%. The nonsynonymous to
synonymous mutation ratio in the remain-
ing 22 expressed genes and the 19 unex-
pressed genes were 2.83 and 2.71,
respectively, consistent with the lack of
selection expected if most are passenger
genes (Chapman et al., 2011).
Of the NOTCH1 mutations, which
occurred in 20% of IGHV-unmutated
and 7% of IGHV-mutated CLL, 29/31
were the P2515Rfs*4. Thismutation previ-
ously had been identified in lymphoid
malignancies, including T cell acute
lymphoblastic leukemia and B-CLL. The
P2515Rfs*4 mutation and the other two
NOTCH 1 mutations all generate prema-
ture stop codons predicted to result in
truncated proteins lacking the destabiliz-
ing PEST domain. The authors confirmed
that leukemias carrying the NOTCH1
P2515Rfs*4 mutation expressed higher
levels of truncated NOTCH1, together
with higher levels of NOTCH1 target
genes. In addition, the NOTCH1 mutation
is correlated with a more advanced clin-
ical stage at diagnosis, a shorter survival,
and an increased frequency of transfor-
mation into diffuse large B cell lymphoma
(DLBCL). All of the MYD88 mutations,ell 20, July 12, 2011 ª2011 Elsevier Inc. 5
Table 1. Global Detection of Coding Mutations: Five Hematopoietic Tumors
TUMORa # Sequencesa # AAb Frequent targetsc # tested % Coding changes Comments
HCL 1 WE 5 BRAF 48 100 all V600E
AML 2 WG 10 DNMT3 281 22 R882 in 37/62 Mostly AML-5 and 4
NPM1 180 24
IDH1 188 9
N-RAS 182 9
9 WE 7 DNMT3 112 21 R882 in 30/32 Mostly AML-5 and 4
NPM1 112 26
FLT3 112 19
N-RAS 112 11
HL 2 RNA.seq CIITA fusion 55 15
PMBCL – CIITA fusion 77 38 4/131(3%) DLBCL
CLL 4 WG 10 NOTCH1 255 12 P2515Rfs*4 in 29/31 20% of unmutated CLL
MYD88 310 3 All L265P
XPO1 165 2 E571K/G All 4 unmutated CLL
KLHL6 160 2 aa 49-90 All 3 mutated CLL,
also in 1/38 MM
MM 23 WG 35 NFKB pathway 38 29 Mostly inactivation
of neg. regulators
13 genes/11 tumors
K-RAS 38 26 aa 13,19,61,63,64,146
N-RAS 38 24 aa 13,61
FAM46C 38 13 1 apparently inactivating
mut. I46fs
4/5 are hyperdiploid
16 WE 28 DIS3 38 11 All missense 3/4 are t(4;14)
BRAF 199 4 2/4 V600E
KLHL6 38 2 F97L
a Abbreviations in text.
b Average nonsynonymous amino acid changes per tumor.
c Targets mutated inR 2% of tumors surveyed, but select samples in MM.
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mutated and 5.6% of the IGHV-mutated
CLL, were the L265P that recently has
been reported to activate NFKB in some
lymphoma (Ngo et al., 2011). All XPO1
mutations affected codon 571, suggest-
ing they are activating mutations, and
are all found in patients with IGHV-unmu-
tated CLL. In contrast, KLHL6 was found
mutated only in three patients with
IGHV-mutated CLL, with a pattern of
mutation consistent with introduction
during the process of somatic hypermuta-
tion of immunoglobulin genes. Interest-
ingly, KLHL6 had been reported to be
mutated in the same region (between resi-
dues 49 and 90) in one patient with
multiple myeloma (MM). If, as the authors
suggest, KLHL6 is a target of the somatic
hypermutation process, the presence of
recurrent mutations in IGHV-mutated
CLL and MM might indicate that this is
a passenger and not a driver mutation. If
these mutations are mediated by the6 Cancer Cell 20, July 12, 2011 ª2011 Elsevisomatic hypermutation process, one
would expect that synonymousmutations
in this region of KLHL6 will be detected in
normal or tumor postgerminal center B
cells. In any case, additional experiments
will determine if mutant KLHL6 is a driver
mutation.
It is of interest to compare this compre-
hensive genomic study of mutations in
four CLL tumors with recent studies on
four other kinds of hematopoietic tumors
(Table 1).
Whole exome sequencing (WES) of the
purified tumor cells from a single patient
with hairy cell leukemia (HCL) identified
five nonsynonymous somatic mutations
(Tiacci et al., 2011). One of the mutations
was the V600E mutation of BRAF, which
is present often inmelanoma and papillary
thyroid cancers and infrequently in MM.
They then examined 47 additional HCL
tumors and found the BRAF V600E muta-
tion in all of them! Obviously, this result
needs to be corroborated by others.er Inc.Two groups have performed WGS on
two M1 subtype acute myeloid leukemia
(AML-M1) tumors (Ley et al., 2010; Mardis
et al., 2009), and WES on nine AML-M5
tumors(Yan et al., 2011), respectively.
The first group identified eleven and ten
genes with somatic mutations affecting
protein coding in the two AML-M1 tumors.
For each tumor, three of the genes were
recurrently mutated in a larger panel of
AML tumors. The second group identified
66 somatic mutations, including 58 single
base changes and 8 indels, affecting 63
genes in nine AML-5 tumors. Fourteen of
these mutations were present recurrently
in a larger panel of AML-5 tumors.
A study on MM reported 23 WGS and
16 WES results for 38 paired normal and
MM samples (Chapman et al., 2011). By
WGS, there was an average of 35 nonsy-
nonymous coding mutations, 0.6 indels,
and 21 DNA rearrangements per tumor,
but WES detected only 28 amino acid-
changing mutations. Although nearly 200
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tumor, the authors estimated that only
ten genes were mutated at statistically
significant rates. However, they attached
significance to identical mutations occur-
ring in different tumors, functionally
related mutations in a pathway (e.g.,
NFKB-activating mutations), clinically
relevant mutations (e.g., BRAF, including
some that were V600E), histone-modi-
fying enzymes, and mutations that might
impact microenvironment interactions.
Finally, a recent study used whole-tran-
scriptome paired-end sequencing to
identify fusion transcripts (Steidl et al.,
2011). The authors initially identified 14
and five predicted fusion transcripts,
respectively, in two Hodgkin’s lymphoma
(HL) cell lines. They then focused on
fusions involving CIITA and identified
recurrent translocations that fused the 50
end of CIITA to multiple partner genes in
15% of HL and 38% of primary medias-
tinal B cell lymphoma (PMBCL), which
phenotpically is related to HL, but in only
3% of DLBCL. Additional studies showed
that the hybrid protein made from the
fusion transcripts had several potential
effects on tumor-microenvironment inter-
actions that favored survival of the tumor.
Comprehensive genome analysis is
identifying important genetic abnormali-ties in hematologicmalignancies. Regard-
less, distinguishing driver and passenger
mutations remains a daunting task. In
these early studies of hematopoietic
tumors, most putative driver mutations
arepresent in only a small fractionof tumor
cells, suggesting great molecular diversity
even for an apparently single clinical
disease. Clearly, many additional samples
will need tobesequenced toobtain amore
complete picture. However, it will be
important to focus also on changes other
than nonsynonymous coding changes,
e.g., mutations in regulatory regions,
structural variationswith long-rang effects
on gene expression, and changes in the
expression and forms of noncoding RNA.
Ultimately, to make sense of all these
findings, it will be critical to perform multi-
dimensional analysis of large cohorts of
patients, ideally uniformly treated, with
serial samples collected longitudinally at
different disease stages, and comprehen-
sively analyzed in terms of DNA (including
epigenetic modifications), RNA, and
protein structure and function.
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In the May 26th issue of the New England Journal of Medicine, de Bono et al. report that the inhibition of
androgen synthesis by abiraterone acetate prolonged the survival of men with prostate cancer previously
treated by androgen suppression.HugginsandHodgespresented the results
of what may be the first translational clin-
ical trial of targeted therapy for cancer in
1941, when circulating androgen levels
were reduced by bilateral orchiectomy inmen with progressive metastatic prostate
cancer (Huggins and Hodges, 1941). To
test the benefit of castration, changes in
serum acid phosphatase, a biomarker of
prostate cancer, and in alkaline phosha-tase, a biomarker of bone destruction
at metastatic sites, were monitored,
revealing marked decreases that accom-
panied improvements in bone pain and
other disease-related symptoms. In theell 20, July 12, 2011 ª2011 Elsevier Inc. 7
